Sales growth driven by continued strong performance from Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc) and Pluvicto (+30% cc) Core operating income ...

Mukul Mehta, currently Head of Business Planning and Analysis (BPA), Digital Finance and Tax, has been appointed Chief Financial Officer, effective March 16, 2026, and will join the Executive ...

Encontre vagas disponíveis na Novartis Brasil com base em seus interesses e habilidades.

View recent presentations and learn more about upcoming events.

Coartem® (artemether-lumefantrine) Baby becomes first malaria treatment approved for newborn babies and young infants Rapid approvals in eight African countries now expected under a special global ...

Browse through the wide range of Novartis multimedia resources at your disposal.

A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment with the product. By reporting side effects ...

The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran. The complete response letter is due to unresolved facility inspection-related ...

Audit & Finance BD&L & Strategic Planning Commercial & General Management Communications & Public Affairs Data and Digital Facilities & Administration Human Resources Information Technology ...

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review ...

Novartis is committed to deploying AI systems in a transparent and responsible way. We will ensure that the use of AI systems has a clear purpose, respectful of human rights, and is accurate, truthful ...

Patients with serious or life-threatening diseases or conditions sometimes seek medical products that are not yet approved or available in their country. Novartis “Managed Access” addresses this need ...